Department of Pharmacology
Fabrice Dabertrand is an Assistant Professor in the Departments of Anesthesiology and Pharmacology at the University of Colorado, Anschutz Medical Campus, USA. He started his training in Chantal & Jean Mironneau’s laboratory and received a Ph.D. in Neurosciences in 2006 from the University of Bordeaux, France, where he also did a first postdoctoral training mentored by Dr. Jean-Luc Morel to study the effect of microgravity on cerebral arteries.
In 2009, he joined the University of Vermont for a second postdoctoral training mentored by Drs. Joseph Brayden and Mark Nelson. There, he developed approaches to study the control of cerebral blood flow in physiological and small vessels disease conditions, with a special interest in the interaction between neural activity and the parenchymal microvasculature. His early studies focused on the control of smooth muscle and endothelial cell function by ion channels, providing some of the first measurements of membrane potential, calcium signaling and diameter imaging of mouse isolated and pressurized intracerebral arterioles. Developing these approaches in murine microcirculation was a tour de force that let him to use genetic mouse models and investigate potential treatments for cerebral diseases with a vascular component, like CADASIL. These accomplishments lead to several article highlights and awards including the New Investigator Award from The American Physiological Society in 2015. He was recruited as faculty at the Anschutz Medical Campus in 2018
Currently, Dr. Dabertrand’s federally funded work (NHLBI/NIH) is aimed at understanding the disruption of neurovascular coupling in disorders involving extracellular matrix alterations to shed light on vascular dementia.
Stress-induced glucocorticoid signaling remodels neurovascular coupling through impairment of cerebrovascular inwardly rectifying K+ channel function.
Proceedings of the National Academy of Sciences of the United States of America May, 2014 | Pubmed ID: 24808139
A PLCγ1-dependent, force-sensitive signaling network in the myogenic constriction of cerebral arteries.
Science signaling , 2014 | Pubmed ID: 24866019
Blood brain barrier precludes the cerebral arteries to intravenously-injected antisense oligonucleotide.
European journal of pharmacology Jan, 2015 | Pubmed ID: 25510229
Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel disease.
Proceedings of the National Academy of Sciences of the United States of America Feb, 2015 | Pubmed ID: 25646445